“As InterVenn accelerates its development as a commercial company, it is the right time to bring on seasoned leadership with experience driving novel precision diagnostics and medicines to market,” said Jenny Rooke, PhD, Founder and Managing Director of Genoa Ventures and Chair of InterVenn’s Board of Directors. “From the beginning, Genoa has been on the journey with InterVenn to realize the exceptional potential of glycoproteomics to provide necessary specificity for precision medicine applications. We are grateful to the work of former CEO and co-founder, Aldo Carrascoso, for leading the company to this stage and are looking forward to working with the new management team to realize the vision of InterVenn’s platform technology.”

As the leader in glycoproteomics, InterVenn analyzes the unique variants at glycosylation for each protein enabling high specificity for precision diagnostics and medicines. To date, InterVenn has launched validated laboratory-developed tests for metastatic melanoma and ovarian cancer. In addition, the company has made its proprietary technology platform available for strategic partners to access the insights of the glycoproteome for research purposes. Estigarribia takes on the CEO role at InterVenn as the company’s platform is ready for commercialization. Early progress has demonstrated the potential for the platform to transform early disease detection and how medical teams understand and treat disease. Estigarribia and his team will expand the market applications of the platform as well as the scope of partnering capabilities.

“The evolution of InterVenn into a commercial company is the next step toward achieving our deeply-held belief that no one should be blindsided by disease,” said Estigarribia, InterVenn’s new CEO. “InterVenn is entering an important new phase of our development, commercialization strategy, and execution to scale the business, increase value creation and drive market adoption of our groundbreaking glycoproteomics-based products. I look forward to my new role at InterVenn and continued work with our extraordinary team.”

Before joining InterVenn, Estigarribia spent more than two decades in global life sciences companies, including executive-level positions at Nugen, CardioDX, and Applied Proteomics and earlier in his career he held leadership positions of increasing responsibility in operations at Chiron, Novartis, and Geron. During his tenure at Applied Proteomics, he played an integral role in launching the best-in-class, blood-based colorectal cancer LDT diagnostic, the SimpliPro Colon Test. Estigarribia holds a Bachelor’s degree in Chemical and Bioprocessing Engineering (with honors) from Swinburne University of Technology, Melbourne Australia. His extensive experience in molecular diagnostics and precision medicine, including leading commercial operations, product development and the launch of pioneering products for clinical use, will be integral in InterVenn’s commercial growth and product development.

Laura Beggrow joins the management team as Chief Commercial Officer with over 25 years of leadership experience in biopharmaceutical and molecular diagnostic industries, most recently having served as Chief Business Officer at Pillar Biosciences. She also held executive leadership positions at HTG Molecular, Celcuity, NantHealth and Strand Diagnostics. Prior to Strand Diagnostics, she served in a variety of commercial roles, including Vice President, Sales and Marketing at Genomic Health from 2004-2013 where she built the foundation of the commercial organization that developed successful market strategies for the breast and colon cancer franchises. Early in her career, Beggrow held various commercial roles in the biopharmaceutical industry. Her distinguished career has focused on commercialization, corporate development and people leadership. Beggrow received her Bachelor of Science Degree in Nursing from The Ohio State University.

“I have spent my career working to bring novel innovations to market that improve patient care,” said Laura Beggrow, the new Chief Commercial Officer at InterVenn. “I am thrilled to be joining InterVenn on its journey to revolutionize early cancer detection and improve the understanding of disease through the power of glycoproteomics.”

About InterVenn Biosciences

InterVenn is a life science company unlocking the value of glycoproteomics—glycosylated proteins which are responsible for driving protein function—for the development of transformational healthcare solutions. The glycoproteome is a source of life-critical information about human biology that has the potential to significantly improve patient outcomes, but it has remained inaccessible due to its vast complexity. InterVenn has pioneered a new AI-powered platform to decode this layer of biology at a clinically meaningful scale for the first time in history. The company’s platform is capable of producing a robust pipeline of powerful clinical applications, ranging from early disease screening to diagnostics and potentially therapeutics. Its proprietary technology platform is accessible to pharma partners, seeking rich biology insights to propel their research and development efforts. Additionally, InterVenn will launch a laboratory-developed test for colon cancer in the second half of 2023. Founded by Nobel Laureate Dr. Carolyn Bertozzi, world-class scientist and distinguished professor Dr. Carlito Lebrilla and leading AI/ML expert Aldo Carrascoso, InterVenn will contribute to making the new era of personalized, predictive, and preventative care a reality. For more information about InterVenn, visit www.intervenn.com.